Indication
Anti-Synthetase Syndrome
1 clinical trial
1 product
Product
CAB-201Clinical trial
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory MyopathyStatus: Recruiting, Estimated PCD: 2028-07-01